Transaction DateRecipientSharesTypePriceValue
9th October 2020Chau Quang Khuong91Grant/award etc.$130.00$11,830.00
2nd October 2020Advisors Llc Orbimed296,000Open or private purchase$25.00$7,400,000.00
2nd October 2020Advisors Llc Orbimed200,000Open or private purchase$25.00$5,000,000.00
1st October 2020Advisors Llc Orbimed296,296Open or private purchase$6.00$1,777,776.00
1st October 2020Advisors Llc Orbimed46,784,775Grant/award etc.$1.07$50,059,709.25
1st October 2020Advisors Llc Orbimed545,974Open or private purchase$6.00$3,275,844.00
1st October 2020Advisors Llc Orbimed639,212Open or private purchase$6.00$3,835,272.00
1st October 2020Advisors Llc Orbimed11,969,619Grant/award etc.$1.07$12,807,492.33
29th September 2020Advisors Llc Orbimed380,133Conversion of derivative$0.00
29th September 2020Advisors Llc Orbimed114,039Conversion of derivative$0.00
Next Cure
Next Cure logo

NextCure, Inc. is a clinical-stage biopharmaceutical company. It is developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function.

Ticker: NXTC
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1661059
Employees: 44
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags